Celgene said it agreed to buy Juno Therapeutics for $87 a share in cash, or about $9 billion, in a move that will expand Celgene's portfolio of blood-cancer drugs. Former KPMG Executives Charged With Conspiracy. Six accountants, including former partners at KPMG LLP, were arrested Monday ...
Delivered by KPMG Today (@KPMG_TO)
Article continues here
Follow @KPMG_TO on Twitter to get latest updates
